Skip to main content
Equibles
ENDV logo

ENDV · Endonovo Therapeutics, Inc.

Track ENDV — free

Use ENDV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENDV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 9
Rebalance outlook locked
Going-concern doubt — flagged Dec 29, 2023

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt as to its ability to continue as going concern within one year from issuance date of these unaudited consolidated financial statements.”
View the 10-Q filed Dec 29, 2023
Market Cap
$31,875
Shares
318.75M
Volume · Nov 9 500K Avg daily vol (3M) 753.37K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.00 Avg vol 30d728K Short int519K · 0.2% of shares · 1.0d Short vol100% DataJan 2020–Nov 2026 Filing10-Q · Dec 29

Latest documents

2024
2023
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$255,723
Trailing 12 months
Net income (TTM)
−$4.40M
Trailing 12 months
Revenue growth YoY
-86.1%
Year over year
Operating margin
-1,023.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$7.09M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+779.4%
Year over year · more shares
Price change (1Y)
+0.0%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Weak Quant / Vol High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg 0%
above
Price vs 50-day avg 0%
above
RSI (14) 45
neutral
MACD trend Negative
Momentum
relative strength
Weak
1-month return 0%
trailing
6-month return 0%
trailing
YTD return 0%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.16% of shares out · ▲ +0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Weak
Revenue growth −33%
Y/Y
Gross margin 410%
expanding
Free cash flow $-681.4K
Balance sheet $7.2M
net debt
Quant / Vol
risk profile
High
Volatility 537%
annualized · 1-yr
Max drawdown −67%
past year
ATR 0.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
1 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
0% Neutral
Price vs 50-day avg
0% Neutral
RSI (14)
45 Neutral
MACD trend
Negative Bearish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.16% of shares out · ▲ +0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Price range unavailable — no recent comparable closes.

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENDV
Endonovo Therapeutics, Inc.
this stock
$31,875 +0.0% -32.9% — 0.2%
VRTX
Vertex Pharmaceuticals Inc
 $137.57B +19.7% +46.2% 34.9 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.40B +23.2% +20.8% 21.0 2.1%
MRNA
Moderna, Inc.
 $93.61B +684.5% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
519.0K
Days to cover
1.0d
Change
+1 sh
View
Short Volume
Short vol %
100%
As of
Nov 11, 2026
Short Total
View
Fails to Deliver
FTD shares
211.9K
Value
$2.1K
As of
Dec 26, 2023
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 28, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$135.4K
Net income (FY)
$-18.5M
View
Filings
SEC Filings
Latest
8-K
Filed
Jan 3, 2024
This year
0
View

Performance

5D 20D 120D MTD YTD
ENDV +0.0% +0.0% +0.0% +0.0% +0.0%
SPY +0.1% -3.3% +2.6% -0.4% +10.4%
vs SPY -0.1% +3.3% -2.6% +0.4% -10.4%
Key facts CIK 1528172 Visit website